Corbus Pharmaceuticals Holdings, Inc.CRBPNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank74
5Y CAGR-23.7%
Year-over-Year Change
Year-over-year operating income growth rate
5Y CAGR
-23.7%/yr
Long-term compound
Percentile
P74
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 10.04% |
| Q3 2025 | -27.49% |
| Q2 2025 | 3.15% |
| Q1 2025 | -56.88% |
| Q4 2024 | 18.70% |
| Q3 2024 | -41.11% |
| Q2 2024 | -14.18% |
| Q1 2024 | 4.75% |
| Q4 2023 | -6.49% |
| Q3 2023 | -15.86% |
| Q2 2023 | 52.66% |
| Q1 2023 | -60.20% |
| Q4 2022 | -31.97% |
| Q3 2022 | -11.46% |
| Q2 2022 | 13.82% |
| Q1 2022 | 14.81% |
| Q4 2021 | 27.94% |
| Q3 2021 | 16.92% |
| Q2 2021 | -8.35% |
| Q1 2021 | 25.94% |
| Q4 2020 | 38.74% |
| Q3 2020 | 10.92% |
| Q2 2020 | -27.62% |
| Q1 2020 | -9.91% |
| Q4 2019 | -8.34% |
| Q3 2019 | -1571.76% |
| Q2 2019 | 106.43% |
| Q1 2019 | -50.77% |
| Q4 2018 | -18.08% |
| Q3 2018 | -20.21% |
| Q2 2018 | -4.46% |
| Q1 2018 | -9.23% |
| Q4 2017 | -56.13% |
| Q3 2017 | 4.59% |
| Q2 2017 | 2.16% |
| Q1 2017 | 1.58% |
| Q4 2016 | -41.97% |
| Q3 2016 | -27.25% |
| Q2 2016 | -45.18% |
| Q1 2016 | -15.45% |